Larimar Therapeutics (STU:ZA71) Beta: 0.6456 (As of Jun. 28, 2026)


STU:ZA71 Larimar Therapeutics Inc STU:ZA71
34 GF Score
Price €3.16
! 2 Warning Signs
View Full Analysis

What is Larimar Therapeutics Beta?

Larimar Therapeutics STU:ZA71 +3.27% 34 Beta is 0.6456 as of Jun. 28, 2026. GuruFocus rates STU:ZA71 with a GF Score™ of 34/100. The stock has 2 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-28), Larimar Therapeutics's Beta is 0.6456.


Larimar Therapeutics  (STU:ZA71) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Larimar Therapeutics Beta Related Terms


Larimar Therapeutics Beta Historical Data

* Premium members only.

The historical data trend for Larimar Therapeutics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Larimar Therapeutics Beta Chart

Larimar Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial 0.00 0.00 2.24 -0.37 0.31

Larimar Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.87 0.13 1.69 0.31 1.30

STU:ZA71 vs GLSI, RGNX, PBYI: Beta Comparison

For the Biotechnology subindustry, Larimar Therapeutics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Larimar Therapeutics Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Larimar Therapeutics's Beta distribution charts can be found below:

* The bar in red indicates where Larimar Therapeutics's Beta falls into.


STU:ZA71
34GF Score
Larimar Therapeutics Inc STU:ZA71
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Larimar Therapeutics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.6456 mean?
Larimar Therapeutics (STU:ZA71) has a Beta of 0.6456 as of Jun. 28, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Larimar Therapeutics and its competitors.
Is Larimar Therapeutics' Beta too high?
Larimar Therapeutics' current Beta is 0.6456. Overall, Larimar Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Larimar Therapeutics' Beta compare to GLSI and RGNX?
Larimar Therapeutics' Beta of 0.6456 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Larimar Therapeutics and its competitors. Larimar Therapeutics's current Beta is 0.6456. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Larimar Therapeutics stock overvalued right now?
Larimar Therapeutics (STU:ZA71) has a current Beta of 0.6456. The current Beta is 0.6456. Larimar Therapeutics' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Larimar Therapeutics (STU:ZA71), the current Beta is 0.6456 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Larimar Therapeutics Business Description

Other Exchanges LRMR:USAZA71:Germany
Address Three Bala Plaza East, Suite 506, Bala Cynwyd, PA, USA, 19004
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
34GF Score

Get the complete analysis for STU:ZA71

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.16
Price